BioSpace News Archive

Who are Americans more likely to take health advice from…their doctors or an Instagram influencer? Would U.S. adults rather talk or text? Socialize in real life or scroll through social media?

Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2019 fourth quarter and fiscal year 2019 results on Tuesday, October 15, 2019, at 4:30 PM E.T.

Eyevensys a private, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco

We are increasingly concerned by the substantial rise of vaping among Canadian youth. As nicotine in any form is highly addictive, non-smokers who vape products containing nicotine are at risk of going on to use tobacco products such as cigarettes.

Global health service company Cigna announced it will add some new plans in Orlando and will extend its highly rated Medicare Advantage plans to the Daytona Beach and Tampa areas.

bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer Society’s National Lung Cancer Roundtable (NLCRT), a collaborative whose membership is focused on reducing both the incidence of lung cancer and mortality rates from the disease.

Quantzig, a global data analytics and advisory firm that delivers actionable analytics solutions to resolve complex business problems, has announced the completion of their latest real world evidence engagement for a pharmaceutical industry client.

Income Research + Management (“Income Research” or “the Firm”), today announced the appointment of Bill O’Malley, a 25-year veteran of the Firm and one of its Managing Principals, as the Firm’s Chief Executive Officer and Co-Chief Investment Officer, effective January 1, 2020

AMAG Pharmaceuticals, Inc. announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials and its voluntary open-label one year extension studies were published in Obstetrics & Gynecology These publications are currently available online and will appear in the November print issue.

H. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals (NASDAQ: ALDR) (Alder) each filed updated tender offer materials with the U.S. Securities and Exchange Commission (SEC) in connection with Lundbeck’s pending tender offer (the Offer)